Evidence grade: WEAK — Supported only by weak or preliminary evidence.
computed from the encoded evidence by the Atlas grading rule.
RANO 2.0 drops routine T2/FLAIR measurement to reduce noise and inter-reader variability; post-radiation scan as baseline reduces pseudoprogression misclassification
Non-enhancing infiltrative progression (esp. IDH-mutant, treated, anti-angiogenic) is clinically real; removing it risks under-calling true progression that enhancement misses
Directly changes trial endpoints and time-to-progression; affects when patients are switched off therapy
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.